Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research

Nam Trung Nguyen†, Taisuke Nakahama†, Duc Hoang Le², Le Van Son², Ha Hoang Chu² and Tadamitsu Kishimoto†*

1 Laboratory of Immune Regulation, WPI-Immunology Frontier Research Center, Osaka University, Suita, Japan
2 National Key Laboratory of Gene Technology, Institute of Biotechnology, Vietnam Academy of Science and Technology, Hanoi, Vietnam
3 Department of RNA Biology and Neuroscience, Graduate School of Medicine Osaka University, Suita, Japan

Edited by: Paolo Puccetti, University of Perugia, Italy
Reviewed by: Teresa Zelante, University of Perugia, Italy; Paolo Puccetti, University of Perugia, Italy; Francisco Javier Quintana, Harvard Medical School, USA
*Correspondence: Tadamitsu Kishimoto, Laboratory of Immune Regulation, WPI-Immunology Frontier Research Center, Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan e-mail: kishimoto@ifrec.osaka-u.ac.jp
†Nam Trung Nguyen and Taisuke Nakahama have contributed equally to this work.

Aryl hydrocarbon receptor (AHR) is thought to be a crucial factor in the regulation of immune responses. Many AHR-mediated immunoregulatory mechanisms have been discovered, and this knowledge may enhance our understanding of the molecular pathogenesis of autoimmune inflammatory syndromes such as collagen-induced arthritis, experimental autoimmune encephalomyelitis, and experimental colitis. Recent findings have elucidated the critical link between AHR and indoleamine 2,3-dioxygenase (IDO) in the development of regulatory T cells and Th17 cells, which are key factors in a variety of human autoimmune diseases. Induction of IDO and IDO-mediated tryptophan catabolism, together with its downstream products such as kynurenine, is an important immunoregulatory mechanism underlying immunosuppression, tolerance, and immunity. Recent studies revealed that induction of IDO depends on AHR expression. This review summarizes the most current findings regarding the functions of AHR and IDO in immune cells as they relate to the pathogenesis of autoimmune diseases in response to various stimuli. We also discuss the potential link between AHR and IDO/tryptophan metabolites, and the involvement of several novel related factors (such as microRNA) in the development of autoimmune diseases. These novel factors represent potential therapeutic targets for the treatment of autoimmune disorders.

Keywords: dioxin receptor, indoleamine 2,3-dioxygenase, transcription factor, autoimmunity, immune regulation

ROLES OF AHR IN THE IMMUNE SYSTEM

Aryl hydrocarbon receptor (AHR) is a ligand-activated member of the Per–Arnt–Sim (PAS) family of basic helix–loop–helix (HLH) transcription factors. AHR mediates cellular responses to toxins or its ligands, including TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 2-(1H-indole-3­’-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), and p23. Once bound to its ligands, the AHR complex translocates to the nucleus and binds the AHR nuclear translocator (Arnt). The resultant AHR–Arnt heterodimers bind specific motifs, called dioxin-responsive elements (DREs), in the promoter region of target genes. These targets, the so-called AHR battery genes, include CYP1A1, CYP1A2, CYP1B1, and other members of the cytochrome P450 family. Several pathways are involved in the regulation of AHR, including proteasomal degradation of AHR, ligand metabolism by CYP1A1, and formation of the AHR–Arnt complex.

IDO AND TRYPTOPHAN METABOLITES

Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting enzyme in extrahepatic catabolism of the essential amino acid tryptophan.
via the kynurenine pathway (44). IDO is constitutively expressed in placenta, but is also highly expressed in epididymis, gut, lymph nodes, spleen, thymus, and lung (45). IDO converts tryptophan into kynurenine and other downstream metabolites, some with neuroactive properties, such as kynurenic acid, 3-hydroxykynurenine, quinolinic acid (QUIN), and serotonin. Deficiency or overexpression of IDO can result in changes in the levels of these neuroactive IDO-mediated metabolites, ultimately leading to neuronal disorders. For instance, elevated levels of QUIN, a potently neurotoxic N-methyl-D-aspartate (NMDA) receptor agonist, can cause not only neurodegenerative conditions such as Huntington’s disease (46) and Parkinson’s disease (47), but also infections of the central nervous system and psychiatric diseases such as depression (48). On the other hand, in pregnant mice, IDO may play a role in preventing the rejection of allogeneic fetuses (49). In addition, blocking IDO activity with the competitive inhibitor 1-methyl tryptophan (1-MT) selectively disrupts the maintenance of pregnancy in mice (49, 50). Consistent with the observations that IDO induces tolerance in allogeneic fetuses, IDO expression, especially in DCs, suppresses the T cell response (49, 51, 52). Various mediators can induce IDO expression and activity, including IFN-γ, TNF-α, IL-1β, and IL-6 (53–58). Recent work showed that the induction of IDO depends on AHR (31, 59, 60). Furthermore, kynurenine has been identified as a potent AHR agonist (2, 61, 62).

Immunoregulatory IDO activity and tryptophan metabolites participate in the regulation of many cell types, including T cells, DCs, monocytes, macrophages, and microglia, that play specific roles in immune responses and regulate the development of immune-mediated inflammatory diseases (62–66). Alberati-Giani et al. showed that IFN-γ induced the expression of IDO activity in immortalized murine macrophages (MT2) and microglial (N11) cells. IFN-γ-treated MT2 cells, but not N11 cells, were able to produce detectable amounts of radio labeled 3-hydroxyanthranilic and QUIN from L-[5-3H] tryptophan. In addition, Heyes et al. demonstrated that increased activities of IDO, kynurenine-3-hydroxylase, and kynureninase in infiltrating primary macrophages may accelerate the synthesis of QUIN, L-kynurenine, and kynurenic acid in conditions of brain inflammation (48). Taken together, these findings suggested that infiltrating macrophages may contribute high amount of cerebral QUIN in brain inflammation (48, 67). Besides, IDO has been demonstrated to be constitutively expressed in DCs (68). Particularly, CD8α+ DC exhibited high functional activity of IDO while CD8− fraction of DC did not exhibit significant enzyme activity (68). Moreover, it has been shown that the expression of IDO makes CD8+ DC treated with IFN-γ capable of affecting apoptosis of T helper type 1 (Th1) cells (68, 69). Fallarino et al. also found that tryptophan metabolites such as 3-hydroxyanthranilic and QUIN induce the selective apoptosis in vitro of murine Th1 cells at relatively low concentrations of kynurenines (70). Together, IDO and kynurenines metabolites are able to be induced in various cell types under different stimuli regulating many immune responses. Modulation of IDO activity and/or kynurenine pathway may develop therapeutics for inflammatory diseases. In addition to IDO, tryptophan 2,3-dioxygenase (TDO) originated from liver and neuron, is also an important rate-limiting enzyme in the tryptophan metabolism. TDO plays a pivotal role in tumor development and various diseases in the brain (61, 71–73).

The transcriptional regulation of IDO is mediated by two main pathways, IFN-γ-dependent and -independent, which involve transcription factors such as NF-κB, STAT-1, and IRF-1 (74). We will discuss the translational regulation of IDO by AHR in the following section.

**TRANSLATIONAL REGULATION OF IDO**

Although the regulatory roles of IDO in tryptophan metabolism in immune regulation have been extensively studied, the mechanisms by which IDO is controlled at the pre-, co-, and post-translational levels are poorly understood. Fujigaki et al. demonstrated that IDO activity is regulated by post-translational modification: specifically, IDO activity is inhibited by peroxynitrite due to the nitration of tyrosine residues (Tyr15, Tyr345, and Tyr353) (75). The same group also demonstrated that an N-terminal alanine of IDO is acetylated in IFN-γ-stimulated THP-1 cells, but the biological significance of this modification has not been fully investigated (76, 77). In addition, another group found that Tyr115 and Tyr253 in mouse IDO can be phosphorylated, and these phosphorylations are required for formation of the IDO/SOCS3 complex (78). This complex is ubiquitinated and subsequent posttranslationally degraded in DCs. These studies indicate that post-translational modifications such as nitration and phosphorylation of tyrosine in IDO may affect IDO/kynurenine-mediated immune regulation. Recently, we showed that the miR-132/212 cluster participates in AHR-dependent generation of Th17 cells (79). miRs, 20–22-nucleotide non-coding RNAs, are a new class of regulators of gene expression at the posttranscriptional level. miRs binding to the 3′ UTR of target mRNAs, leading to translational inhibition and/or degradation of the targets (80). Although numerous immunoregulatory genes are controlled by miRs, to date no miRs targeting IDO have been identified. According to a widely used computational miR target prediction tool, microRNA.org, several miRs potentially regulate IDO mRNA (http://www.micromrna.org/micromrna/home.do). For example, miR-203 has a putative binding site in the 3′ UTR of IDO in mouse. Interestingly, this miR is induced by AHR ligands such as TCDD and BaP, and it negatively affects AHR expression in human cancer cell lines (81). In addition, it has been reported that miR-203 in macrophage RAW264.7 cells negatively regulates LPS-induced IL-6 and TNF-α by targeting MyD88 (82). Considering that AHR inhibits pro-inflammatory cytokines production such as IL-6 and TNF-α in LPS-stimulated macrophages as similarly to miR-203, miR-203 may also be involved in AHR-mediated regulation of inflammatory responses in macrophages. Although experimental verification is necessary in order to confirm this possible relationship between miR and IDO mRNA, identification of miR-mediated regulation of the IDO pathway may shed light on novel mechanisms of immune regulation.

**AHR/IDO AXIS IN PATHOGENESIS IN AUTOIMMUNE DISEASE**

For several decades, AHR has been studied as an important transcription factor involved in regulation of a large superfamily of genes encoding cytochrome p450 proteins, which are xenobiotic metabolizing enzymes. Two independent groups demonstrated that AHR controls the generation of regulatory T (Treg) cells...
and/or IL-17-producing T helper (Th17) cells in EAE, a mouse model of MS (17, 41). Because the balance between Treg and Th17 cells is now considered to be more important than the Th1/Th2 balance in regard to the onset of autoimmunity, AHR has attracted increased attention in the context of immunology. To investigate the pathophysiological roles of AHR in autoimmunity, several groups have studied mouse models of autoimmune disease, such as colitis and rheumatoid arthritis, using AHR-KO mice and/or AHR ligands (83–85). Meanwhile, the roles of AHR in various immune cells such as DCs and macrophages have also been investigated (16, 25, 60). In DCs, AHR positively regulates IDO expression and subsequent kynurenine production (60). In addition, Kimura et al. observed reduced phosphorylation of STAT-1 in AHR-deficient macrophages; by contrast, AHR acts as a negative regulator of STAT-1 activation in T cells under Th17-polarizing conditions (15, 16). Thus, the effect of AHR on STAT-1 status is complex, and may be cell type- or stimulus-dependent. Given that expression of IDO is predominantly controlled by the IFN-γ/STAT-1 axis, AHR may positively control STAT-1 activation and subsequent IDO expression in DCs. More importantly, kynurenine is an agonist of AHR, and may participate in a positive-feedback loop in AHR signaling. In both plasma and CSF from MS patients, tryptophan levels were significantly reduced (86). In addition, IFN-β treatment, a first-line immunomodulatory treatment for MS, causes elevation of IDO mRNA and plasma or serum kynurenine (87, 88). As well as the observation in MS patients, EAE induction leads to alteration of the ratio of kynurenine and tryptophan or IDO expression in brain and spinal cord (89, 90). On the other hand, in spite of evidence that IDO is induced by IFN-γ, IDO expression is negatively correlated with IFN-γ mRNA levels in brain and spinal cord. This observation suggests that IDO activity inhibits the generation of IFN-γ-producing Th1 cells, a primary subset of pathogenic T cells (89). Consistent with these findings, deletion of IDO in mice and treatment with the IDO inhibitor 1-MT result in exacerbated disease symptoms in association with elevated levels of Th1 cells (89–91). We previously showed that LPS- or CpG-stimulated AHR-deficient BMDCs co-cultured with naïve T cells contain a smaller proportion of Treg cells and elevated levels of Th1 and Th17 (60). Furthermore, the aberrant generation of each Th-cell subset can be rescued by kynurenine. These observations indicate that kynurenine generates a tolerogenic condition by controlling not only Th1, but also Th17 and Treg cells. In addition, it has been reported that AHR participates in type 1 regulatory T (Tr1) cell generation in vitro and in vivo (18, 92, 93). Thus, we cannot exclude the possibility that not only TCDD and FICZ, but also kynurenine regulates Tr1 cell induction. Taken together, further investigation of the roles of kynurenine in T cell differentiation may reveal potential therapeutic strategies for MS. Thus, further investigation of the roles of kynurenine in T cell differentiation may reveal potential therapeutic strategies for MS. Immune regulation through the AHR/IDO axis is summarized in Figure 1.

**Figure 1** | TLR ligands trigger transcriptional activation of STAT-1 and NF-κB, and then induce IDO mRNA. Although AHR forms complex with STAT-1 and NF-κB in macrophages under pro-inflammatory cytokines production, whether this complex is appeared in DC or required for IDO expression is not known. Induced IDO mRNA may be controlled by miR-203 (not investigated), and the activity or amount of IDO protein is regulated at post-translational modification such as nitration of Tyr and ubiquitin ligation. Kynurenine catalyzed by IDO induces tolerance via regulating the balance of TH1, TH17, Tr1, and Treg. Kynurenine may activate the AHR for IDO induction with autocrine manner, and form AHR/Kynurenine positive-feedback loop.
Aryl hydrocarbon receptor and tryptophan metabolites participate in experimental models of autoimmune diseases (4, 17, 26, 41, 42, 61, 85, 94–96). However, the possible role of AHR in dioxin-exposed people is still unknown, particularly in autoimmune disorders. Therefore, it will be interesting to examine the expression of AHR and AHR-related genes in dioxin-affect ed people with the aim of identifying the potential link between AHR induction and dioxin-related autoimmune diseases. Future investigations should focus on determining whether activation of AHR leads to stimulation of IDO expression, and consequently promotes production of tryptophan metabolites such as kynurenine, which potentially mediate the neurological disorders and/or autoimmune diseases in dioxin-exposed people. Promising therapeutics based on intervention in the AHR/IDO axis may help to improve the health outcomes of dioxin exposure.

ACKNOWLEDGMENTS

This work was supported by the Kishimoto Foundation and Project CSK14-02 (for Nam Trung Nguyen) from the Institute of Biotechnology, Vietnam Academy of Science and Technology.
53. Musso T, Gusella GL, Brooks A, Longo DL, Varesio L. Interleukin-4 inhibits Terness P, Bauer TM, Röse L, Dufter C, Watzlik A, Simon H, et al. Inhibition of T lymphocyte proliferation by IL-4: role of IL-4 receptors on IL-4 sensitive cells. J Immunol (2003) 171:223–31. doi:10.4049/jimmunol.167.2.207
54. Babcock TA, Carlin JM. Transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. J Interferon Cytokine Res (2003) 23:413–21. doi:10.1089/inter.2003.23.413
55. Robinson CM, Shirey KA, Carlin JM. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. J Interferon Cytokine Res (2003) 23:413–21. doi:10.1089/inter.2003.23.413
56. Moreau M, Lestage J, Verrier D, Mormede C, Kelley KW, Dantzer R, et al. Bacille Calmette-Guérin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxigenase in mice. J Infect Dis (2005) 192:537–44. doi:10.1086/431603
57. Conner TJ, Stole N, O’Sullivan JR, Harkin A. Induction of indoleamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge; a role for IFN-gamma? Neurosci Lett (2008) 441:29–34. doi:10.1016/j.neulet.2008.06.007
58. Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H, et al. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflamma-
tory cytokines. J Biochem (2006) 139:655–62. doi:10.1093/jb/mfp072
59. Vogel CFA, Goth SR, Dong B, Pessah IN, Matsumura F. Aryl hydrocarbon receptor
signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun (2008) 375:331–5. doi:10.1016/j.bbrc.2008.07.156
60. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenic-
ity via a kynurenine-dependent mechanism. Proc Natl Acad Sci USA (2010) 107:19961–6. doi:10.1073/pnas.1007416107
61. Opitz CA, Litzenburger UM, Sahn F, Ott M, Triticshler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon recep-
tor. Nature (2011) 478:197–203. doi:10.1038/410re1332
62. Bessedes A, Gargaro M, Pallotta MT, Matino D, Servillo G, Bruunacci C, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature (2014) 514:184–90. doi:10.1038/nature1332
63. Guillenin GJ, Kerr SJ, Pemberton LA, Smith DG, Smythe GA, Armati PJ, et al. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment. J Interferon Cytokine Res (2001) 21:1291–300. doi:10.1016/s0192-0561(00)000301
64. Jung ID, Lee CM, Jeong YI, Lee IS, Park WS, Han J, et al. Differential regulation of indoleamine 2,3-dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells. FEBs Lett (2007) 581:1449–56. doi:10.1016/j.febslet.2007.02.073
65. O’Connor JC, Lawson MA, André C, Moreau M, Lestage J, Castanon N, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry (2009) 14:511–22. doi:10.1038/mp.2009.214
66. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 12:870–8. doi:10.1038/ni.2077
67. Alberati-Giani D, Riccardi-Castagnoli P, Köhler C, Cesura AM. Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J Neurochem (1996) 66:994–1006. doi:10.1002/jn.1831160608
68. Fallarino F, Vacca C, Orabona C, Belladonna ML, Bianchi R, et al. Functional expression of indoleamine 2,3-dioxygenase by murine CD8α(-) dendritic cells. Int Immunol (2002) 14:655–63. doi:10.1093/intimm/dx146
69. Grohmann U, Fallarino F, Bianchi R, Belladonna ML, Vacca C, Orabona C, et al. IL-6 inhibits the tolerogenic function of CD8α(-) dendritic cells expressing indoleamine 2,3-dioxygenase. J Immunol (2001) 167:708–14. doi:10.4049/jimmunol.167.2.708
70. Fallarino F, Grohmann U, Vacca C, Orabona C, Sprecia A, Fioretti MC, et al. T cell apoptosis by kynurenines. Adv Exp Med Biol (2003) 537:183–90. doi:10.1007/978-1-4615-0135-0_21
71. Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, Matsumoto K, et al. Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain (2009) 2:8. doi:10.1186/1756-6606-2-8
72. Pirotte L, Larrieu P, Sroostant V, Colau D, Dolusic E, Frédérick R, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci USA (2012) 109:2497–502. doi:10.1073/pnas.1113731109
73. Adamas S, Brady N, Bessedes A, Brew BJ, Grant R, Teo C, et al. The kynurenine pathway in brain tumor pathogenesis. Cancer Res (2012) 72:5649–57. doi:10.1158/0008-5472.CAN-12-0549
74. Campbell BM, Charych E, Lee AW, Möller T. Kynurenines in CNS disease: reg-
ulation by inflammatory cytokines. Front Neurosci (2014) 8:12. doi:10.3389/fnins.2014.00012

www.frontiersin.org

October 2014 | Volume 5 | Article 551 | 5

Nguyen et al.

Dioxin receptor and IDO
75. Fujigaki H, Saito K, Lin F, Fujigaki S, Takahashi K, Martin BM, et al. Nitration and inactivation of IDO by peroxynitrite. J Immunol (2006) 176:372–9. doi:10.4049/jimmunol.176:1.372
76. Fujigaki H, Takahashi K, Fujigaki S, Masuda J, Takikawa O, Markey SP, et al. Post-translational modification of indoleamine 2,3-dioxygenase: N-terminal modification and nitration. Int Congr Ser (2007) 1304:41–5. doi:10.1007/s00216-012-5946-2
77. Fujigaki H, Seishima M, Saito K. Post-translational modification of indoleamine 2,3-dioxygenase. Anal Bioanal Chem (2012) 403:1777–82. doi:10.1007/s00216-012-5946-2
78. Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, et al. SOCS3 drives posttranslational degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci USA (2008) 105:20828–33. doi:10.1073/pnas.0810278105
79. Nakahama T, Hanieh H, Nguyen NT, Chinen I, Ripley B, Millrine D, et al. Activation of the aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17-producing T-helper cell differentiation. Proc Natl Acad Sci U S A (2013) 110:11964–9. doi:10.1073/pnas.1310871110
80. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell (2009) 136:215–33. doi:10.1016/j.cell.2009.01.002
81. Li D, Liu C, Yo H, Zeng X, Xiong X, Chen L, et al. AhR is negatively regulated by mIR-203 in response to TCDD or BaP treatment. Toxicol Lett (2014) 234:45–51. doi:10.1016/j.toxlet.2013.03.004
82. Wei J, Huang X, Zhang Z, Jia W, Zhao Z, Zhang Y, et al. MyD88 as a target of microRNA-203 in regulation of lipopolysaccharide or Bacille Calmette-Guérin induced inflammatory response of macrophage RAW264.7 cells. Mol Immunol (2013) 55:303–9. doi:10.1016/j.molimm.2013.03.004
83. Takamura T, Harama D, Matsuoka S, Shimokawa N, Nakamura Y, Okumura K, et al. Activation of the aryl hydrocarbon receptor pathway may ameliorate dextran sodium sulfate-induced colitis. Immunol Cell Biol (2010) 88:685–9. doi:10.1038/icb.2010.35
84. Furumatsu K, Nishiumi S, Kawano Y, Otani M, Yoshie T, Shiomi Y, et al. A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig Dis Sci (2011) 56:2532–44. doi:10.1007/s10620-011-1643-9
85. Nakahama T, Kimura A, Nguyen NT, Chinen I, Hanieh H, Nohara K, et al. Aryl hydrocarbon receptor deficiency in T cells suppresses the development of collagen-induced arthritis. Proc Natl Acad Sci USA (2011) 108:14222–7. doi:10.1073/pnas.1111761108
86. Monaco F, Fumero S, Montino A, Mutani R. Plasma and cerebrospinal fluid aryl hydrocarbon receptor expression in multiple sclerosis patients. J Neuro Immunol Psychiatry (1979) 42:640–1. doi:10.1136/jnpp.42.7.640
87. Amirkhani A, Rajda C, Arvidsson B, Bencsik K, Roda K, Seres E, et al. Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients. Eur J Neurol (2005) 12:625–31. doi:10.1111/j.1468-1331.2005.00411.x
88. Durastanti V, Lagares A, Bramanti P, Amato M, Bellantone P, De Luca G, et al. Neopterin production and tryptophan degradation during 24-months therapy with interferon-beta-1a in multiple sclerosis patients. J Transl Med (2011) 9:42. doi:10.1186/1479-5876-9-42
89. Sakurai K, Zou JP, Tchetetter JR, Ward JM, Shearer GM. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol (2002) 129:186–96. doi:10.1016/S0165-5728(02)00176-5
90. Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. PASEB J (2005) 19:1347–9. doi:10.1009/jf.04-03-32807e
91. Yan Y, Zhang GX, Gran B, Fallarino F, Yu S, Li H, et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol (2010) 185:5953–61. doi:10.4049/jimmunol.1001628
92. Wu HY, Quintana FJ, da Cunha AP, Duke BT, Koeglsperger T, Starosson SC, et al. In vivo induction of Th1 cells via mucosal dendritic cells and AHR signaling. PLoS One (2011) 6:e22618. doi:10.1371/journal.pone.0022618
93. Gandhi R, Kumar D, Burns EL, Nadeau M, Duke B, Laroni A, et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol (2010) 11:846–53. doi:10.1038/ni.1915
94. Plattner M, Ho PP, Youssef S, Fontoura P, Garren H, Hua EM, et al. Treatment of autoimmune neurinflammation with a synthetic tryptophan metabolite. Science (2005) 310:850–5. doi:10.1126/science.1117634
95. Nguyen NT, Hanieh H, Nakahama T, Kishimoto T. The roles of aryl hydrocarbon receptor in immune responses. Int Immunol (2013) 25:335–43. doi:10.1093/intimm/dxt111
96. Nguyen NT, Nakahama T, Kishimoto T. Aryl hydrocarbon receptor and experimental autoimmune arthritis. Semin Immunopathol (2013) 35:637–44. doi:10.1007/s00281-013-0392-6

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 30 July 2014; paper published pending: 05 September 2014; accepted: 16 October 2014; published online: 29 October 2014.

Citation: Nguyen NT, Nakahama T, Le DH, Van Son L, Chu HH and Kishimoto T (2014) Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front. Immunol. 5:551. doi: 10.3389/fimmu.2014.00551

This article was submitted to Immunological Tolerance, a section of the journal Frontiers in Immunology.

Copyright © 2014 Nguyen, Nakahama, Le, Van Son, Chu and Kishimoto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.